Open AccessEfficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study
Author(s) -
John H. Strickler,
Antonio Cubillo,
Jian Liang,
Marc Matrana,
Mark Kozloff,
T. E. Lowe,
Martha Blaney,
Mohammad Sahtout,
Louie Naumovski,
Zev A. Wainberg
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-1603
Subject(s) - folfiri , bevacizumab , medicine , colorectal cancer , hazard ratio , oncology , irinotecan , tolerability , adverse effect , surgery , cancer , chemotherapy , confidence interval